Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC

PC Tumeh, MD Hellmann, O Hamid, KK Tsai… - Cancer immunology …, 2017 - AACR
We explored the association between liver metastases, tumor CD8+ T-cell count, and
response in patients with melanoma or lung cancer treated with the anti-PD-1 antibody …
被引用次数：484 相关文章

Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC

PC Tumeh, MD Hellmann, O Hamid… - Cancer …, 2017 - pubmed.ncbi.nlm.nih.gov
We explored the association between liver metastases, tumor CD8+ T-cell count, and
response in patients with melanoma or lung cancer treated with the anti-PD-1 antibody …

Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC

PC Tumeh, MD Hellmann, O Hamid… - Cancer Immunology …, 2017 - pure.johnshopkins.edu
We explored the association between liver metastases, tumor CD8+ T-cell count, and
response in patients with melanoma or lung cancer treated with the anti-PD-1 antibody …

Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC

PC Tumeh, MD Hellmann, R Dummer - Cancer Immunology …, 2017 - zora.uzh.ch
We explored the association between liver metastases, tumor CD8+ T-cell count, and
response in patients with melanoma or lung cancer treated with the anti-PD-1 antibody …

Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC

PC Tumeh, MD Hellmann, O Hamid… - Cancer Immunology …, 2017 - escholarship.org
We explored the association between liver metastases, tumor CD8+ T-cell count, and
response in patients with melanoma or lung cancer treated with the anti-PD-1 antibody …

Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC

PC Tumeh, MD Hellmann, O Hamid, KK Tsai… - Cancer Immunology …, 2017 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> We explored the association between liver
metastases, tumor CD8+ T-cell count, and response in patients with melanoma or lung …
[PDF] researchgate.net

[PDF][PDF] Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC

RH Pierce, A Daud, KK Hamid, KL Loo, MA Gubens… - Cancer, 2017 - researchgate.net
We explored the association between liver metastases, tumor CD8+ T-cell count, and
response in patients with melanoma or lung cancer treated with the anti-PD-1 antibody …
[HTML] nih.gov

[HTML][HTML] Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC

PC Tumeh, MD Hellmann, O Hamid… - Cancer immunology …, 2017 - ncbi.nlm.nih.gov
We explored the association between liver metastases, tumor CD8+ T-cell count, and
response in patients with melanoma or lung cancer treated with the anti-PD-1 antibody …

Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC.

PC Tumeh, MD Hellmann, O Hamid… - Cancer Immunology …, 2017 - europepmc.org
We explored the association between liver metastases, tumor CD8+ T-cell count, and
response in patients with melanoma or lung cancer treated with the anti-PD-1 antibody …

[引用][C] Liver metastasis and treatment outcome with anti‐PD‐1 monoclonal antibody in patients with melanoma and NSCLC. Cancer

PC Tumeh - Immunol Res, 2017 - cir.nii.ac.jp
Liver metastasis and treatment outcome with anti‐PD‐1 monoclonal antibody in patients with
melanoma and NSCLC. Cancer | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …